BiotechTube
PeproMene Bio

PeproMene Bio

Duarte, United States· Est.
pepromenebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

PeproMene Bio is a private, clinical-stage biotech focused on developing BAFF-R-targeting immunotherapies for B-cell cancers and autoimmune disorders. Its lead asset, PMB-CT01 (BAFFR CAR-T), is in Phase 1 trials for relapsed/refractory B-ALL and mantle cell lymphoma, with early clinical data showing promise. The company leverages foundational intellectual property from City of Hope and MD Anderson and is supported by strategic partnerships and investment, positioning it to address antigen escape in CD19-targeted therapies.

OncologyAutoimmune Disorders

Technology Platform

Platform centered on targeting the B-cell Activating Factor Receptor (BAFF-R) using a novel antibody, enabling the development of CAR-T cells, allogeneic CAR-NK cells, and bispecific antibodies designed to overcome antigen escape in B-cell malignancies.

Funding History

2
Total raised:$25M
Series A$20M
Seed$5M

Opportunities

The primary opportunity is addressing the significant unmet need in patients with B-cell malignancies who relapse after CD19-targeted therapies due to antigen loss.
Success could position PeproMene as a leader in next-generation, resistance-overcoming cell therapies.
A secondary, large opportunity exists in applying BAFF-R-targeted B-cell depletion to autoimmune diseases.

Risk Factors

Key risks include clinical trial failure, intense competition in the CAR-T and B-cell therapy space, the complex and costly manufacturing of cell therapies, and reliance on raising additional capital to fund operations and clinical development.

Competitive Landscape

PeproMene competes in the crowded B-cell malignancy therapy space, directly against approved CD19 CAR-T products (e.g., Kymriah, Yescarta) and companies developing therapies targeting other B-cell antigens (e.g., CD20, CD22). Its differentiation hinges on the novelty of the BAFF-R target and its potential to overcome CD19 antigen escape, a known limitation of current standards of care.

More companies in Biologics / Biosimilars →More companies in United States →